company background image
MYX

Mayne Pharma Group ASX:MYX Stock Report

Last Price

AU$2.83

Market Cap

AU$242.7m

7D

-6.3%

1Y

-49.5%

Updated

07 Feb, 2023

Data

Company Financials +

MYX Stock Overview

Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe and Asia.

MYX fundamental analysis
Snowflake Score
Valuation5/6
Future Growth1/6
Past Performance0/6
Financial Health2/6
Dividends0/6

My Notes

New

Notes are coming soon

Mayne Pharma Group Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Mayne Pharma Group
Historical stock prices
Current Share PriceAU$2.83
52 Week HighAU$8.50
52 Week LowAU$0.22
Beta0.86
1 Month Change-32.62%
3 Month Change-49.46%
1 Year Change-49.46%
3 Year Change-66.31%
5 Year Change-79.19%
Change since IPO-76.42%

Recent News & Updates

Analysts Just Slashed Their Mayne Pharma Group Limited (ASX:MYX) EPS Numbers

Dec 03
Analysts Just Slashed Their Mayne Pharma Group Limited (ASX:MYX) EPS Numbers

Recent updates

Analysts Just Slashed Their Mayne Pharma Group Limited (ASX:MYX) EPS Numbers

Dec 03
Analysts Just Slashed Their Mayne Pharma Group Limited (ASX:MYX) EPS Numbers

Is Mayne Pharma Group (ASX:MYX) Using Too Much Debt?

Dec 01
Is Mayne Pharma Group (ASX:MYX) Using Too Much Debt?

Is Mayne Pharma Group (ASX:MYX) A Risky Investment?

Apr 12
Is Mayne Pharma Group (ASX:MYX) A Risky Investment?

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Mar 01
Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

We Think Mayne Pharma Group Limited's (ASX:MYX) CEO Compensation Package Needs To Be Put Under A Microscope

Nov 16
We Think Mayne Pharma Group Limited's (ASX:MYX) CEO Compensation Package Needs To Be Put Under A Microscope

Mayne Pharma Group (ASX:MYX) Is Making Moderate Use Of Debt

Nov 10
Mayne Pharma Group (ASX:MYX) Is Making Moderate Use Of Debt

Mayne Pharma Group (ASX:MYX) Is Carrying A Fair Bit Of Debt

May 17
Mayne Pharma Group (ASX:MYX) Is Carrying A Fair Bit Of Debt

Is Mayne Pharma Group Limited (ASX:MYX) Trading At A 37% Discount?

Mar 22
Is Mayne Pharma Group Limited (ASX:MYX) Trading At A 37% Discount?

How Many Mayne Pharma Group Limited (ASX:MYX) Shares Did Insiders Buy, In The Last Year?

Mar 01
How Many Mayne Pharma Group Limited (ASX:MYX) Shares Did Insiders Buy, In The Last Year?

What You Need To Know About Mayne Pharma Group Limited's (ASX:MYX) Investor Composition

Feb 08
What You Need To Know About Mayne Pharma Group Limited's (ASX:MYX) Investor Composition

Mayne Pharma Group Limited's (ASX:MYX) Shift From Loss To Profit

Jan 18
Mayne Pharma Group Limited's (ASX:MYX) Shift From Loss To Profit

Mayne Pharma Group's (ASX:MYX) Shareholders Are Down 75% On Their Shares

Dec 27
Mayne Pharma Group's (ASX:MYX) Shareholders Are Down 75% On Their Shares

Would Mayne Pharma Group (ASX:MYX) Be Better Off With Less Debt?

Dec 09
Would Mayne Pharma Group (ASX:MYX) Be Better Off With Less Debt?

A Quick Analysis On Mayne Pharma Group's (ASX:MYX) CEO Compensation

Nov 24
A Quick Analysis On Mayne Pharma Group's (ASX:MYX) CEO Compensation

Shareholder Returns

MYXAU PharmaceuticalsAU Market
7D-6.3%-1.0%0.5%
1Y-49.5%-28.9%1.8%

Return vs Industry: MYX underperformed the Australian Pharmaceuticals industry which returned -28.9% over the past year.

Return vs Market: MYX underperformed the Australian Market which returned 1.8% over the past year.

Price Volatility

Is MYX's price volatile compared to industry and market?
MYX volatility
MYX Average Weekly Movement9.6%
Pharmaceuticals Industry Average Movement9.6%
Market Average Movement8.4%
10% most volatile stocks in AU Market15.5%
10% least volatile stocks in AU Market3.4%

Stable Share Price: MYX is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: MYX's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2005n/aShawn O’Brienhttps://www.maynepharma.com

Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe and Asia. The company operates through four segments: Metrics Contract Services, International, Branded Products, and Portfolio Products. It provides oral drug delivery systems; and contract pharmaceutical development, manufacturing, and analytical services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women’s health, and infectious disease therapeutic areas.

Mayne Pharma Group Limited Fundamentals Summary

How do Mayne Pharma Group's earnings and revenue compare to its market cap?
MYX fundamental statistics
Market CapAU$242.75m
Earnings (TTM)-AU$263.34m
Revenue (TTM)AU$424.80m

0.6x

P/S Ratio

-0.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MYX income statement (TTM)
RevenueAU$424.80m
Cost of RevenueAU$253.77m
Gross ProfitAU$171.03m
Other ExpensesAU$434.37m
Earnings-AU$263.34m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Feb 23, 2023

Earnings per share (EPS)-3.07
Gross Margin40.26%
Net Profit Margin-61.99%
Debt/Equity Ratio72.8%

How did MYX perform over the long term?

See historical performance and comparison